The trick is finding the right treatment plan for you. “COPD can come in a few different varieties. Some people have just ...

These drugs, which open airways and reduce swelling, are a cornerstone of COPD treatment, making inhaler devices and medications the talk of the town at the Congress’ ERS panels and symposia.

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Smoking is the most common aetiologic factor. Evidence for the treatment of patients with mild-to-moderate COPD is limited. Here, the authors show that long-term treatment with high-dose N ...

Here, Tan and other experts in the field describe how this new understanding of inflammation is informing treatment. And it's ...

It is important that clinicians are able to stratify disease severity and exacerbation risk in treatment for patients with chronic obstructive pulmonary disease (COPD), says Klaus Rabe ...

Opens in a new tab or window The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on ...

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

The drug, Dupixent, showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies. The drug was previously approved for the treatment of other ...